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Background: A deficiency of muscle phosphofructokinase (PFKM) causes a rare
metabolic muscle disease, the Tarui disease (Glycogen storage disease type VII, GSD
VII) characterized by exercise intolerance with myalgia due to an inability to use glucose
as an energy resource. No medical treatment for GSD VII currently exists. The aim of this
study was to determine whether a dietary intervention with excessive fat intake would
benefit GSD VII.
Patient and Methods: A ketogenic diet (KD) intervention implemented as a modified
Atkins diet was established for one patient with PFKM deficiency, with a low late lactate
response and very high ammonia levels associated with exercise. We recorded the KD
intervention for a total of 5 years with clinical and physiotherapeutic evaluations and
regular laboratory parameters. Cardiopulmonary exercise testing, including breath gas
analysis and venous lactate and ammonia measurements, was performed before KD
and at 3, 8 months and 5 years after initiation of KD.
Results: During the 5 years on KD, the patient’s muscle symptoms had alleviated and
exercise tolerance had improved. In exercise testing, venous ammonia had normalized,
the lactate profile remained similar, but oxygen uptake and mechanical efficiency had
increased and parameters showing ventilation had improved.
Conclusions: This study is the first to show a long-term effect of KD in GSD VII with
an alleviation of muscle symptoms, beneficial effects on breathing, and improvement
in exercise performance and oxygen uptake. Based on these findings, KD can be
recommended under medical and nutritional supervision for selected patients with GSD
VII, although further research of this rare disease is warranted.
Keywords: Tarui disease, GSDVII, ketogenic diet, cardiopulmonary exercise capacity, lactate, ammonia, glykogen
storage disease
INTRODUCTION
Tarui disease or muscle phosphofructokinase (PFKM) deficiency belongs to the glycogen storage
diseases (GSD VII, OMIM#232800). It is a rare autosomal recessive disorder caused by mutations
in the PFKM gene and characterized by exercise intolerance, muscle cramping, and myoglobinuria
associated with compensated hemolysis and later nascent muscle weakness and mild myopathy
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(1, 2). Phosphofructokinase is the rate-limiting enzyme in the
glycolytic pathway and catalyzes the phosphorylation of fructose
6-phosphate to fructose-1, 6-bisphosphate. In Tarui disease,
typically the total lack of phosphofructokinase enzyme in muscle
tissue causes the oxidative pathway from glucose to pyruvate
to be blocked at this point of the glycolysis pathway, and
glucose cannot be used in muscle energy metabolism normally.
Therefore, the muscle tissue in Tarui disease must utilize
alternative oxidative substrates other than glucose in energy
metabolism. In McArdle’s disease (GSD V, #232600), a condition
resembling Tarui disease, increased fat oxidation during exercise
has been reported (3). The importance of free fatty acids for
muscle oxidative metabolism has also been revealed in Tarui
disease, and patients with this disease have been shown to benefit
from substrates available after overnight fasting or triglyceride
infusion during aerobic exercise (4). Indeed, glucose would
not have a favorable effect on their cardiorespiratory capacity,
and glucose ingestion could even worsen the condition (4, 5).
Patients with Tarui disease, unlike in McArdle’s disease, do not
show the second-wind phenomenon, an exercise-related increase
in the capacity for muscle oxidative phosphorylation (6, 7).
In both diseases, an excess of purine metabolites, e.g., uric
acid, hypoxanthines, and ammonia, as an indicator of increased
utilization of proteins has been found (8).
Currently, no specific treatment options exist for Tarui
disease. Regular physiotherapy is important, although a benefit
from slowly progressive exercise training has not been established
(6, 7). However, a diet low in carbohydrates and high in fat and
protein (ketogenic diet, KD) could hypothetically be beneficial
for patients. In order to understand the benefit of KD in the long
term we present the results of a careful 5 years follow-up with
blood specimens, clinical visits, and cardiopulmonary exercise
testing with blood gas, ammonia, and lactate examinations on a
male patient suffering from Tarui disease (9, 10).
PATIENT AND METHODS
Patient
The patient is a 59 years-old man carrying a homozygous
PFKM gene mutation, c.329G>A. The histological and genetic
findings (9) and the analyses of the exercise lactate profile
(10) have been published earlier. In childhood, he had normal
motor development and normal exercise tolerability, but was
not very keen on sports. As a young boy he could run up
to 100 meters but around the age of 12 years he started to
develop symptoms, including muscle weakness, and attacks of
muscle pain, weakness, cramping, and vomiting, during extensive
physical activity. He was never hospitalized due to the muscle
symptoms or due to raise in creatine kinase (CK) values.
At age 59, there was mild muscle weakness in hip flexors and
extensors and ankle flexors and extensors on the right side [MRC
scale 4 out of 5 (11)], mild reticulocytosis without anemia, and
normal EMG. No muscle atrophy was evident. Medication for
high blood pressure had been recently introduced (amlodipin
5mg and valsartan 160mg once a day). The patient’s weight was
71 kg and height 177 cm (BMI 23.0 kg/m2). He could walk with
a slow pace about 10 km but walking on an incline was limited
by muscle pain. He could not run, because of muscle cramping
and feeling unwell, and could walk only one flight of stairs. He
did regular hunting and hiking trips in the forest. He annually
spent 4–5 days in Lapland with a group of friends hiking 15–
20 km daily but he was always the last in the group and other
members had to wait for him.
Ethical approval for the study was granted by the Medical
Ethics Committee of Helsinki University Central Hospital,
Finland. Informed consent was provided by the patient and
the controls.
Diet
The patient’s diet was evaluated using a 3 days food record prior
to KD initiation, and the evaluation was repeated 6 months after
starting KD. Dietary intakes were calculated using the national
food composition database of the National Institute for Health
and Welfare, Finland (12). The KD was guided by the same
dietitian (M.S.) throughout the study period. Nutrition and diet
were assessed and counseled at clinic visits or by phone or
email contacts several times during the initiation period and
later at least yearly. Daily energy intake was planned to be at
the same level as before the KD, the amount of carbohydrates
was restricted to 10 g per day, and the consumption of fat and
protein was encouraged, aiming at a ketogenic ratio of ∼1:1.
Consumption of unsaturated fats was recommended to avoid
unfavorable changes in serum lipids. Multivitamin, additional
vitamin D, and calcium supplementations were introduced.
Temporal mitigation of carbohydrate restriction (using small or
moderate amounts of e.g., rye bread) was allowed during the
treatment when disadvantage of the diet was considered (strong
increase of LDL-cholesterol).
Laboratory Assessment
Laboratory parameters were followed up regularly; e.g., β-
hydroxybutyrate, glucose, cholesterol, CK, and liver function
were measured almost monthly during the first year and, after
stabilization of the diet, twice during the second year and
once a year thereafter, except for cholesterol values, which
were measured more often. The laboratory results from the
time points of exercise testing are presented in Table 1. In
addition, concentrations of some vitamins (vitamins D and
A), minerals (such as selenium and zinc), carnitine (total
and free), prealbumin, and urine calcium and creatinine were
measured discretionarily to optimize nutrient intakes. Blood
β-hydroxybutyrate was also measured by the patient at home
to ensure ketosis (target level 2.5–5), at the beginning every
morning and evening, and later on demand.
Cardiopulmonary Exercise Test
Cardiopulmonary exercise test with breath gas analysis
(spiroergometry) was performed as described earlier before KD
and at 3, 8 months, and 5 years after start of KD (13). The test
was started with a 40W work load, with an increase of 40W in
3min increments (40 W/3min). A maximal subjective level of
at least 17/20 on the Borg scale was attained. The venous blood
specimens were taken via a vacuum technique, and the analysis
of lactate and ammonia specimens as well as the venous blood
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TABLE 1 | Laboratory parameters before ketogenic diet (KD) and during the 5













0.22 1.30 0.59 0.4**
Plasma glucose (mmol/L)
4.0–6.0 mmol/L
5.8 5.2 5.3 5.6**
Serum insulin (mU/L)
(2–20 mU/L)
4.1 1.6 1.2 3.5**
Plasma creatine kinase (U/L)
40–280 U/L
96 74 160 159
Plasma alkaline phosphatase (U/L)
35–105 U/L
55* 34 34 Not
measured
Plasma alanine aminotransferase (U/L)
10–70 U/L
33 36 25 27
Plasma glutamyltransferase (U/L)
15–115 U/L
41* 18 24 18**
Plasma triglycerides (mmol/L)
<2.0 mmol/L
2.39 0.64 0.59 0.67
Plasma cholesterol (mmol/L)
<5.0 mmol/L
4.6 5.2 5.6 4.4
Plasma LDL# cholesterol (mmol/L)
<3.0 mmol/L
2.7 3.5 3.5 2.1
Plasma HDL## cholesterol (mmol/L)
>1.0 mmol/L
1.52 1.88 2.15 1.83
Laboratory tests were studied once a month during the first year, three times in the second
year, and annually in years 3–5.
*Measured during KD initiation.




gases and electrolytes have been reported earlier (10). The results
of four healthy men with a mean age of 48 (range 35–60) years
and BMI 23.0 kg/m2 (SD 1.4) were selected from an earlier study
(10) and served as a control. Younger men and women from the
original controls were excluded.
Statistical Methods
Spearman’s correlation test was performed between the baseline
and diet phases for the patient as well as for the controls.
RESULTS
Diet and Laboratory Tests
Before KD, the calculated total energy intake was 2,660 kcal
per day and consisted of 177 g of available carbohydrates (27
E%, percentage of total energy intake), 107 g of protein (16
E%) and 164 g of fats (55 E%). Six months after beginning KD,
the calculated total energy intake was ∼2,880 kcal per day and
consisted of 229 g of fats (72 E%), 189 g of protein (26 E%) and
12 g of available carbohydrates (2 E%), with a ketogenic ratio
of∼1:1.
The β-hydroxybutyrate concentrations measured in
laboratory ranged between 0.4 and 2.9 mmol/L during the
follow-up period mostly being below 2.5 mmol/L (Table 1).
During periodical mitigation of carbohydrate restriction
β-hydroxybutyrate concentration was lower. An increase
was initially seen in cholesterol values, with the highest
concentrations measured after 2 years on KD, total cholesterol
8.2 mmol/L, LDL-cholesterol 6.2 mmol/L and HDL-cholesterol
2.01 mmol/L. Ezetimibe 10mg (Ezetimibe accord R©) medication
was started due to high cholesterol values. Finally, during
medication, total cholesterol, and LDL-cholesterol were below
baseline values and HDL-cholesterol was slightly increased at
5 years control. Plasma glucose and insulin values were within
normal limits before and during KD and both decreased after
beginning of the diet (Table 1).
Vitamin D concentration (serum 25-hydroxyvitamin D3 and
D2) was at the beginning of dietary therapy below reference
values, 32 nmol/L. After vitamin D supplementation, the
concentration increased to 63 nmol/L.
Clinical Examination
Already after 6 months’ exposure to KD, the patient began
to experience a subjective alleviation of muscle symptoms,
manifesting as more rapid recovery and less muscle discomfort.
He was able to increase daily exercise and could gradually spend
extended periods of time hiking and hunting in the forest.
However, he still often suffered from stiffness.
At 5 years, his muscle strength (MRC) was within the normal
range (5 of 5) except for ankle extension forces (4 of 5). Deep
tendon reflexes were present excluding Achilles. He felt that
exercise tolerance had improved during KD and experienced less
cramping and nausea during exercise than before KD. He could
now walk longer without stopping and could ski 10–15 km/day
at the same speed as his friends, which was not possible before
KD. During KD he could participate in long hiking trips, moving
at a similar speed as his peers, also not possible before KD. He
felt that especially capability to walk on an incline was better than
before KD.
The patient’s weight had decreased from 71 to 58 kg (height
177 cm), with BMI falling from 22.7 to 18.5 kg/m2 in 5 years.
Results of Cardiorespiratory Exercise
Testing
The main results of the cardiorespiratory exercise testing during
the follow-up at the time points of 3, 8 months and 5 years
are presented in Table 2. The maximal working capacity was
moderately reduced before KD, increasing slightly during KD,
but it remained lower than the values of age-matched controls.
The maximal oxygen uptake by body weight had a mild increase
during KD and the mechanical efficiency (Wmax/VO2max)
increased from 13.1 to 16.5% (normal value ≥20%).
During KD a decrease occurred in the very high maximal
breathing frequency in exercise, from 68 to 46/min and an
increase in tidal volume from 44.6 to 60.3% of predicted
value. However, slight hyperventilation was found, as assessed
in slightly increased minute ventilation vs. CO2 production
(VE/VCO2) and O2 consumption (VE/VO2) and also in slightly
decreased FetCO2.
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percentage of predicted (%)*
98.3 94.6 94.9 94.8 97.9 (4.6)




0.91 0.88 0.92 0.75 1.13 (0.05)
Wmax/3min (maximal
working capacity) (W)
93 90 99 102 285.2 (81)
V
′
O2 max (maximal oxygen
uptake) (L/min)






28.8 25.9 34.8 30.7 52.1 (12.1)
Wmax/V
′
O2 max (%) 13.1 11.1 14.1 16.5 21.7 (1.4)
Breathing frequency 68 61 56 46 43.0 (12.8)
Tidal volume, % of predicted 44.6 41.7 56.1 60.3 109.8 (24.8)
Fraction of end tidal CO2
(FetCO2) (%)
4.16 3.82 3.8 4.0 5.4 (0.51)
RQ, respiratory quotient; V′CO2 is maximal CO2 production.
*205–0.5 × age.
Results of Venous Blood From Exercise
Testing
The venous lactate level at rest remained at pre-KD level
(1.1 mmol/L) in the follow-up (0.8 mmol/L) (Figure 1). The
ammonia level at rest decreased from 36 to 27 µmol/L. The
maximal ammonia level (measured 4–10min after exercise) was
409 µmol/L before KD (10) and was reduced at 3 months to
half of the pre-KD level. However, a new increase was seen
at 8 months (after the periodical mitigations of carbohydrate
restriction), which at 5 years had returned to normal level, 111
µmol/L (Figure 2). Before KD, metabolic alkalosis was seen after
exercise (pH 7.46 and BE +4.2 mmol/L at 2min after exercise),
but at 5 years the pH value after exercise was within normal limits
(pH 7.38 and BE+ 2.6 mmol/L) (Figure 3).
DISCUSSION
During the 5 years follow-up of KD the patient remained
clinically stable with subjective alleviation of muscle pain
symptoms and better exercise tolerance. In cardiopulmonary
exercise testing, working capacity and mechanical efficiency
had increased. In venous blood, lactate levels had decreased
from the low pre-KD levels, and the very high ammonia levels
associated with exercise testing detected in the measurements
before KD had decreased to normal. KD had a beneficial impact
also on respiratory parameters during exercise, reflected as
lowering of breathing frequency and the ventilatory equivalent
for O2 (V
′
E/O2) and as increasing tidal volume, suggesting
diminished hyperventilation. However, the end tidal CO2
FIGURE 1 | Lactate levels associated with exercise tests of the patient before
diet and during the follow-up. The values of the control subjects without
dietary intervention are also given for comparison. The baseline lactate data
has been published earlier (10), the controls matched to the age and gender of
the patient were obtained from the forementioned publication. A strong
correlation existed between the patient’s baseline lactate values and his diet
curves at 3, 7 months, and 5 years, rho being 0.914 (p = 0.006), 0.885 (p =
0.015), and 0.90 (p = 0.001), respectively.
FIGURE 2 | Ammonia levels associated with exercise tests of the patient
before the diet and during the follow-up. Values of the control subjects without
dietary intervention are also given for comparison. The baseline ammonia data
has been published earlier (10), and the controls matched to the age and
gender of the patient were obtained from the aforementioned publication. No
correlations existed between the baseline curve of the patient and those of the
controls or the diet curves of the patient.
level (FetCO2) remained rather low, indicating permanent
hyperventilation tendency.
Increasing evidence is emerging for a benefit of dietary
therapy, especially in metabolic muscle diseases (14), but also
in dystrophic disorders (15). However, among GSDs specific
enzyme replacement therapy exists only in Pompe’s disease (GSD
II) (16). In McArdle’s disease (GSD V), some data suggest a
benefit of KD in relieving symptoms (17). In one child with
PFKM deficiency presenting with congenital arthrogryposis and
severe myopathy, KD starting at age 4 months alleviated clinical
symptoms, enhanced motor skill development, and improved
muscle strength (18). Before KD, our patient’s diet fat content
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FIGURE 3 | pH levels associated with exercise tests of the patient before the
diet and during the follow-up. Values of the control subjects without dietary
intervention are also given for comparison. The baseline ammonia curve has
been published earlier (10), and the controls matched to the age and gender of
the patient were obtained from the aforementioned publication. A high
negative correlation existed between the patient’s baseline curve and mean
diet curve (rho = −0.826, p = 0.006).
(55 E%) was relatively high and carbohydrate content (27 E%)
low compared with the typical diet of Finnish men (fat 36 E%,
carbohydrates 42 E%) (12), possibly attenuating our findings
on the beneficial effects of KD. The patient’s original diet was
evaluated for the first time before the initiation of KD, but had
remained similar for years.
KD was fairly well-tolerated by the patient. About 7 months
after adopting KD, high LDL-cholesterol level was measured (4.9
mmol/L). Since cardiovascular disease exists among the patient’s
immediate family, the disadvantage of the KD for the patient was
reconsidered, and the restriction of carbohydrates was mitigated
(e.g., rye bread was allowed), which led to a decrease in ketosis.
Based on the patient’s subjective experience of lowered exercise
capability after the increase of carbohydrates, however, the KD
was again tightened. With rising LDL-cholesterol values (up to
6.2 mmol/L) cholesterol-lowering medication was started after 3
years of KD. The LDL-cholesterol level was at the 5 years control
lower than before KD (2.1 vs. 2.7 mmol/L). During follow-up,
no abnormalities were detected in the liver or kidney functions.
The patient’s weight decreased by 13 kg during KD. He was
satisfied with the weight decrease, although it was not the original
aim of the treatment. Interestingly, the reported energy intake
during KD was greater than before KD. This may be due to the
better working capacity, leading to increased physical activity
during the diet. However, it is also possible that the difference
between these calculated intakes is explained by normal day-to-
day variation in food intake since the food record periods were
short (3 days).
The patient’s maximal oxygen uptake (L/min) actually
decreased in the follow-up, but relative to weight oxygen uptake
mildly increased from the pre-KD values [from 91 to 103% of
predicted values (19)]. The benefit of KD was more clearly seen
in the mild increase in maximal working capacity, which rose
from 56 to 68W, with a simultaneous decrease in maximal heart
rate. The mechanical efficiency, which is the maximal working
power during the exercise test relative to the simultaneous
maximal oxygen consumption (uptake), also increased during
KD, reflecting improved exercise performance. However, at
5 years on KD, his exercise capacity remained at 68.1% of
healthy controls’ values (Table 2). The decrease in the respiratory
quotient (RQ, relation of CO2 production to O2 consumption) at
5 years may more be associated with decreased glucose oxidation
and increased fat oxidation (20) than with submaximal effort.
This would be in line with former findings of inverse connection
between free fatty acid concentration and oxidation with insulin
concentration (21) since insulin adequately decreased after
beginning of the KD.
Before KD, a very low lactate level was found in the
cardiopulmonary exercise test, with a delayed increase occurring
10–20min after the exercise (10). During KD the lactate curve
associated with exercise testing had a similar shape as before
the diet, but was situated lower, which is explained by less
ingested carbohydrates. The level of ammonia increased to very
high levels in exercise testing before KD compared with control
subjects (Figure 2) as well as with earlier data on exercise
tests in healthy subjects (22). High levels of ammonia might
cause the patient’s exercise fatigue and short-term neurological
discomfort, as reported also in sport medicine (23, 24), being
one explanation for the increased ventilation, especially during
exercise. With KD, the level of ammonia during exercise was
drastically decreased, attaining normal levels. In line with our
finding, elevated ammonia has earlier been reported in Tarui
disease during exercise testing (8).
A common route to catabolize proteins and nucleotides is
deamination of adenosine monophosphate (AMP) to inosine
monophosphate (IMP) (23–25) which generates ammonia.
In Tarui disease, the increase of ammonia during exercise
has in some reports been explained by impaired cellular
adenosine diphosphate (ADP) phosphorylation and its increased
degradation to AMP (6). The results of our earlier study (10)
suggested that in Tarui disease, glucose passing the normal
glycolytic route could be used in other anabolic biosynthetic
reactions leading to increase of ammonia (26–28).
Just before the exercise test at 8 months the patient
returned to ketosis, and in the exercise test, a new increase
in ammonia was detected. This suggests that even a short
period of more carbohydrates may increase the ammonia level
during the exercise test (Figure 2) highlighting the importance
of carbohydrates in the high ammonia levels associated with
Tarui disease.
Since convincing evidence between higher whole-
grain consumption, which is a substantial contributor to
carbohydrate intake, and lower risk of coronary heart disease,
type 2 diabetes, colorectal cancer and all-cause mortality,
is growing (29), extreme restriction of carbohydrates
has to be well-founded. The risk factors of chronic
diseases must be considered during long-term KD as was
done in our case, with cholesterol-lowering medication
started due to the increase in LDL-cholesterol levels. The
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patient felt that his exercise capability was decreased in
conjunction with increased carbohydrate intake and wanted
to continue the strict KD with subsequent initiation of
cholesterol medication.
During KD associated with the exercise test, pH and base
excess values remained rather high, indicating that no metabolic
acidosis had developed. Carbohydrate intake restriction and
ingested fat and proteins produce acidic ketones, which have a
tendency to advance to metabolic acidosis; however, this was
not seen here. This is probably explained that there still would
have been release of alkaline ammonia from protein catabolism,
although less than before KD.
In our previous study (10), ventilation during exercise of the
patient was markedly increased before KD, which may arise from
lower exercise tolerance and increased ammonia levels during
and after exercise causing neural discomfort. In the present
study, better cardiopulmonary condition and lower ammonia
production possibly lowered the ventilation. Correspondingly, in
an earlier study of Tarui disease, exercise tests during triglyceride
infusion were associated with decreases in ventilation and
respiratory exchange ratio and increases in work intensity and
oxygen uptake (4).
The main strength of this study is that KD was carefully
implemented and followed in a very cooperative patient.
Laboratory examinations were performed continuously, the
follow-up intervals increasing as the patient achieved a balance
with KD. Also the cardiorespiratory exercise testing was first
performed with shorter intervals, and the last test at 5 years to
obtain data on long-termKD treatment. A study limitation is that
we had only one patient, and further studies are needed.
In conclusion, KD intervention in our patient with Tarui
disease seemed to have a beneficial effect, as measured by the
patient’s subjective condition with diminished muscle symptoms
and increases in exercise capacity and oxygen uptake, which also
had a favorable effect on the patient’s ventilation. Cholesterol
values increased on the diet, but with statin medication the
levels were kept under control. Our results thus encourage the
implementation of KD in patients with Tarui disease as the risk
factors of chronic diseases are considered.
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